All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Robert Zeiser, University of Freiburg, Freiburg, DE. We asked, What is the latest update on the GRAVITAS-309 trial?
What is the latest update on the GRAVITAS-309 trial?
In this interview, Zeiser presents the initial results from ASH abstract #771: ‘Itacitinib and Corticosteroids As initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravtias-309.’
Firstly, Zeiser discusses how the anti-inflammatory properties of itacitinib as a JAK 1 inhibitor may be beneficial in chronic GvHD. He goes on to outline the overall efficacy and safety of itacitinib in combination with corticosteroids.
Case study | 51-year-old with chronic GvHD with no improvement after a week on prednisone
A detailed case study of a 51-year-old male patient with chronic GvHD, with an expert opinion from Arnon Nagler on how he would approach this case.
Editorial theme | Latest updates on cGvHD treatment
First-line treatment for chronic graft-versus-host disease (cGvHD), which consists of steroids, has not changed much over the last three decades. In the case of severe cGvHD, another...
Subscribe to get the best content related to GvHD delivered to your inbox